Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel insights into the pathogenesis of follicular lymphoma by molecular profiling of localized and systemic disease forms.
Kalmbach S, Grau M, Zapukhlyak M, Leich E, Jurinovic V, Hoster E, Staiger AM, Kurz KS, Weigert O, Gaitzsch E, Passerini V, Engelhard M, Herfarth K, Beiske K, Micci F, Möller P, Bernd HW, Feller AC, Klapper W, Stein H, Hansmann ML, Hartmann S, Dreyling M, Holte H, Lenz G, Rosenwald A, Ott G, Horn H; German Lymphoma Alliance (GLA). Kalmbach S, et al. Among authors: beiske k. Leukemia. 2023 Oct;37(10):2058-2065. doi: 10.1038/s41375-023-01995-w. Epub 2023 Aug 10. Leukemia. 2023. PMID: 37563306 Free PMC article.
Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine-rituximab.
Ramsower CA, Rosenthal A, Robetorye RS, Mwangi R, Maurer M, Villa D, McDonnell T, Feldman A, Cohen JB, Habermann T, Campo E, Clot G, Bühler MM, Kulis M, Martin-Subero JI, Giné E, Cook JR, Hill B, Raess PW, Beiske KH, Reichart A, Hartmann S, Holte H, Scott D, Rimsza L. Ramsower CA, et al. Among authors: beiske kh. Br J Haematol. 2024 Jan;204(1):160-170. doi: 10.1111/bjh.19153. Epub 2023 Oct 25. Br J Haematol. 2024. PMID: 37881141
Proteomics uncovers molecular features for relapse risk stratification in patients with diffuse large B-cell lymphoma.
Ludvigsen M, Campbell AJ, Enemark MB, Hybel TE, Karjalainen-Lindsberg ML, Beiske K, Bjerre M, Pedersen LM, Holte H, Leppä S, Jørgensen JM, Honoré B. Ludvigsen M, et al. Among authors: beiske k. Blood Cancer J. 2023 Oct 26;13(1):161. doi: 10.1038/s41408-023-00931-6. Blood Cancer J. 2023. PMID: 37884514 Free PMC article. No abstract available.
Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma.
Spasevska I, Sharma A, Steen CB, Josefsson SE, Blaker YN, Kolstad A, Rustad EH, Meyer S, Isaksen K, Chellappa S, Kushekhar K, Beiske K, Førsund MS, Spetalen S, Holte H, Østenstad B, Brodtkorb M, Kimby E, Olweus J, Taskén K, Newman AM, Lorenz S, Smeland EB, Alizadeh AA, Huse K, Myklebust JH. Spasevska I, et al. Among authors: beiske k. Blood Adv. 2023 Dec 12;7(23):7216-7230. doi: 10.1182/bloodadvances.2023010158. Blood Adv. 2023. PMID: 37695745 Free PMC article.
Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas.
Arffman M, Meriranta L, Autio M, Holte H, Jørgensen J, Brown P, Jyrkkiö S, Jerkeman M, Drott K, Fluge Ø, Björkholm M, Karjalainen-Lindsberg ML, Beiske K, Pedersen MØ, Leivonen SK, Leppä S. Arffman M, et al. Among authors: beiske k. Med. 2024 Apr 2:S2666-6340(24)00119-3. doi: 10.1016/j.medj.2024.03.007. Online ahead of print. Med. 2024. PMID: 38579729 Free article.
Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements-an LLMPP study.
Hilton LK, Collinge BJ, Ben-Neriah S, Alduaij W, Shaalan H, Weng A, Cruz M, Slack GW, Farinha P, Miyata-Takata T, Boyle M, Meissner B, Cook JR, Ondrejka SL, Ott G, Rosenwald A, Campo E, Amador C, Greiner TC, Raess PW, Song JY, Inghirami GG, Jaffe ES, Weisenburger DD, Chan WC, Beiske K, Fu K, Delabie J, Pittaluga S, Iqbal J, Wright G, Sehn LH, Savage KJ, Mungall AJ, Feldman AL, Staudt LM, Steidl C, Rimsza LM, Morin RD, Scott DW. Hilton LK, et al. Among authors: beiske k. Blood. 2024 May 3:blood.2024024251. doi: 10.1182/blood.2024024251. Online ahead of print. Blood. 2024. PMID: 38701426
Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.
Park JR, Villablanca JG, Hero B, Kushner BH, Wheatley K, Beiske KH, Ladenstein RL, Baruchel S, Macy ME, Moreno L, Seibel NL, Pearson AD, Matthay KK, Valteau-Couanet D. Park JR, et al. Among authors: beiske kh. Cancer. 2022 Nov 1;128(21):3775-3783. doi: 10.1002/cncr.34445. Epub 2022 Sep 13. Cancer. 2022. PMID: 36101004 Free PMC article.
Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup.
Martinez-Monleon A, Kryh Öberg H, Gaarder J, Berbegall AP, Javanmardi N, Djos A, Ussowicz M, Taschner-Mandl S, Ambros IM, Øra I, Sandstedt B, Beiske K, Ladenstein R, Noguera R, Ambros PF, Gordon Murkes L, Ljungman G, Kogner P, Fransson S, Martinsson T. Martinez-Monleon A, et al. Among authors: beiske k. Sci Rep. 2022 Jul 20;12(1):12420. doi: 10.1038/s41598-022-16455-1. Sci Rep. 2022. PMID: 35859155 Free PMC article.
142 results